47.84

1.81% -0.88

Tarsus Pharmaceuticals Inc (TARS)

Overview News Price History Option Chain Financials Discussions Forecast

Tarsus Pharmaceuticals Inc stock is traded at $47.84, with a volume of 459.23K. It is down -1.81% in the last 24 hours and up +2.35% over the past month. Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.

Previous Close:

$48.72

Open:

$49.77

24h Volume:

459.23K

Relative Volume:

0.82

Market Cap:

$1.83B

Revenue:

$17.39M

Net Income/Loss:

$-135.89M

P/E Ratio:

-10.31

EPS:

-4.64

Net Cash Flow:

$-123.00M

1W Performance:

-4.74%

1M Performance:

+2.35%

6M Performance:

+83.44%

1Y Performance:

+58.78%

1-Day Range:

$47.11

$50.00

1-Week Range:

$47.11

$51.28

52-Week Range:

$20.08

$57.28

Tarsus Pharmaceuticals Inc Stock (TARS) Company Profile

Name

Tarsus Pharmaceuticals Inc

Sector

Healthcare (1169)

Industry

Biotechnology (678)

Phone

(949) 409-9820

Address

15440 LAGUNA CANYON ROAD, IRVINE

Employee

244

Twitter

Next Earnings Date

2024-11-07

Latest SEC Filings

TARS's Discussions on Twitter

Compare TARS with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TARS Tarsus Pharmaceuticals Inc	47.84	1.83B	17.39M	-135.89M	-123.00M	-4.64
VRTX Vertex Pharmaceuticals Inc	484.24	124.35B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	700.33	76.56B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	644.48	39.16B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	250.59	32.44B	2.25B	-278.16M	-42.59M	-2.17
BNTX Biontech Se Adr	120.01	28.77B	3.30B	-501.07M	1.03B	-2.1146

Tarsus Pharmaceuticals Inc Stock (TARS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-20-23	Initiated	Goldman	Neutral
Jul-18-23	Initiated	William Blair	Outperform
May-18-23	Initiated	Guggenheim	Buy
Aug-01-22	Initiated	Barclays	Overweight
Dec-21-21	Initiated	H.C. Wainwright	Buy
Nov-23-21	Initiated	Oppenheimer	Outperform
Nov-10-20	Initiated	BofA Securities	Buy
Nov-10-20	Initiated	Jefferies	Buy
Nov-10-20	Initiated	Ladenburg Thalmann	Buy
Nov-10-20	Initiated	Raymond James	Strong Buy

View All

Tarsus Pharmaceuticals Inc Stock (TARS) Latest News

Feb 20, 2025

Tarsus to Report Fourth Quarter and Full-Year 2024 Financial Results on Tuesday, February 25, 2025 - GlobeNewswire

Feb 20, 2025

When Will Tarsus Share Its Latest Financial Performance? Key Date Revealed - StockTitan

Feb 20, 2025

Feb 19, 2025

Allspring Global Investments Holdings LLC Lowers Stock Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - Defense World

Feb 19, 2025

Allspring Global Investments Holdings LLC Has $10.03 Million Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - Defense World

Feb 19, 2025

Feb 15, 2025

5,825 Shares in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Acquired by Bleakley Financial Group LLC - MarketBeat

Feb 15, 2025

Feb 14, 2025

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Average Recommendation of "Buy" by Brokerages - MarketBeat

Feb 14, 2025

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Sold by abrdn plc - MarketBeat

Feb 14, 2025

Feb 13, 2025

Tarsus Pharmaceuticals (NASDAQ:TARS) Receives "Buy" Rating from Guggenheim - MarketBeat

Feb 13, 2025

Where Are They Now? Tarsus Pharmaceuticals - Life Science Leader Magazine

Feb 13, 2025

Feb 12, 2025

A Bill Maher joke spotlighted Tarsus Pharmaceuticals’ crust mite fight - MM+M Online

Feb 12, 2025

Bleakley Financial Group LLC Purchases Shares of 5,825 Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - Defense World

Feb 12, 2025

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Average Recommendation of “Buy” by Brokerages - Defense World

Feb 12, 2025

Feb 11, 2025

Tarsus Pharmaceuticals’ (TARS) “Buy” Rating Reaffirmed at Guggenheim - Defense World

Feb 11, 2025

Feb 10, 2025

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Sold by SG Americas Securities LLC - Defense World

Feb 10, 2025

Feb 09, 2025

Tarsus Pharmaceuticals (NASDAQ:TARS) Reaches New 12-Month HighShould You Buy? - MarketBeat

Feb 09, 2025

Feb 08, 2025

Long Term Trading Analysis for (TARS) - news.stocktradersdaily.com

Feb 08, 2025

E. Ohman J or Asset Management AB Lowers Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - MarketBeat

Feb 08, 2025

Feb 07, 2025

Is Tarsus Pharmaceuticals (NASDAQ:TARS) Using Too Much Debt? - Simply Wall St

Feb 07, 2025

Tarsus Pharmaceuticals (NASDAQ:TARS) Shares Down 5.3%What's Next? - MarketBeat

Feb 07, 2025